In Memoriam: Carlton Haywood, Jr., PhD

On December 31st Maryland and the entire Sickle Cell community lost a warrior and a researcher. Carlton was a friend of MSCDA. Since our earliest days, Carlton volunteered to share his expertise and time in numerous ways. Presenting at forums, sitting on planning committees and many other ways. Carlton was featured in the Baltimore Sun, using his life’s experiences to bring awareness to SCD. We greatly appreciate Carlton’s many contributions. We offer our sincere condolences to Carlton’s family, his many colleagues, and friends.

For more on Carlton’s life, please click here.

Share this post

Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."